Strategic Partnerships:
Kardigan’s March 2025 acquisition of Prolaio, alongside statements that Prolaio will continue operating independently while leveraging Kardigan’s scale, signals added resources and distribution for scale‑up. Feedback suggests this combination is intended to extend the platform’s reach across researchers, providers, and biopharma.
Market Expansion:
Public materials cite operations in 26+ countries and active, post‑acquisition hiring and role postings, indicating geographic and organizational expansion. The nationwide, all‑remote OCORO Heart Study further reflects expanding field activity and data generation.
Innovation-Driven Growth:
Regulatory milestones—including multiple FDA‑cleared algorithms and the December 2025 eVO2peak clearance—indicate a maturing product and evidence base. Company‑reported millions of patient‑hours and ongoing study activity suggest continued product and research execution.
